Recent Updates
Recently added Catalysts

Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed

Phase 3

Tetanus | Monoclonal antibody | Infectious Disease |Sanofi|Last Updated: May 30, 2017

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials1
Total Enrollment534

FDA Designations

No designations recorded

Clinical trial landscape

Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed · 1 trial · 3 indications

Phase 3 1
NCT02089347Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 - 12 Years OldTetanus
COMPLETED534 Analytics
PHASE3COMPLETED
Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 - 12 Years Old
TetanusUnlock trial analytics

Study Endpoints

Primary Endpoints

Percentage of Participants With Diphtheria and Tetanus Post-vaccination Booster Response Following Vaccination With Either SP306 or DT
Day 28 post-vaccination

Diphtheria booster response was defined as a ≥4-fold rise in pre- to post-vaccination antitoxin concentration in a subject with a pre-vaccination antitoxin concentration ≤ 2.56 IU/mL or a ≥ 2-fold rise in a subject with a pre-vaccination antitoxin concentration \>2.56 IU/mL. A tetanus booster response is defined as a ≥ 4-fold rise in pre- to post-vaccination antitoxin concentration in a subject with a pre-vaccination antitoxin concentration ≤ 2.7 IU/mL or a ≥ 2-fold rise in a subject with a pre-vaccination antitoxin concentration \>2.7 IU/mL. Diphtheria antitoxin concentration was assayed by the toxin neutralization test; Tetanus antitoxin concentration was assayed by the enzyme-linked immunosorbent assay (ELISA) method

Percentage of Participants With Seroprotection to Diphtheria and Tetanus Antigens Post-booster Vaccination With Either SP306 or DT Vaccine
Day 28 post-vaccination

Seroprotection was defined as the proportion of subjects at 28 days post-vaccination with diphtheria and tetanus antitoxin concentration ≥0.1 IU/mL. Diphtheria antitoxin concentration was assayed by the toxin neutralization test; Tetanus antitoxin concentration was assayed by the enzyme-linked immunosorbent assay (ELISA) method

Percentage of Participants With Pertussis Booster Response Following Vaccination With Either SP306 or DT Vaccine
Day 28 post-vaccination

Pertussis booster response was defined as a pre-vaccination antibody concentration less than the lower limit of quantitation (LLOQ) and a post vaccination level ≥ 4XLLOQ; or a pre-vaccination antibody concentration ≥ LLOQ but \< 4XLLOQ and a 4-fold rise (i.e. post/pre-vaccination ≥ 4); or a pre-vaccination antibody concentrations ≥ 4XLLOQ and a 2-fold rise (i.e. post/pre-vaccination ≥2). Pertussis antitoxin concentration were assayed by the enzyme-linked immunosorbent assay (ELISA) method.

Secondary Endpoints

Percentage of Participation With Seroprotection to Diphtheria and Tetanus Antigens Before Vaccination With Either SP306 or DT Vaccine
Pre-vaccination (Day 0)
Percentage of Participants With Seroprotection to Diphtheria and Tetanus Antigens Before and Following Vaccination With Either SP306 or DT Vaccine
Day 0 (pre-vaccination) and Day 28 post-vaccination
Geometric Mean Concentration of Diphtheria and Tetanus Antibodies Before and Following Vaccination With Either SP306 or DT Vaccine
Day 0 (pre-vaccination) and Day 28 post-vaccination
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposePREVENTION

Treatment Arms

ArmTypeDescription
SP306 GroupEXPERIMENTALParticipants randomized to receive SP306 vaccine intramuscularly
DT GroupACTIVE_COMPARATORParticipants randomized to receive DT vaccine subcutaneously

Interventions

NameTypeDescription
Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbedBIOLOGICAL0.5 mL, intramuscularly.
Diphtheria and Tetanus toxoids adsorbedBIOLOGICAL0.1 mL, Subcutaneously
Unlock Study Design Details

Eligibility Criteria

Age Range11 Years to 12 Years
SexALL
Healthy VolunteersYes
Study Sites19

Inclusion Criteria: * Aged 11 or 12 years and considered healthy on the day of inclusion * Informed consent form and assent form signed and dated by the parent(s) / legal representative(s) and the subject respectively * Completed childhood vaccination against diphtheria, pertussis and tetanus (i.e....

Countries:Japan
Unlock Eligibility Criteria